利用 mRNA 生成瞬时 CAR-T 细胞的非病毒方法用于肿瘤免疫治疗 A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy. PubMed 2025/02/21 发表J Vis ExpQ3 · IF 1.2(JCR 2025) 靶点:HER2技术:CAR-T卵巢癌淋巴瘤白血病地区:欧洲
CD19-抗 ErbB2 scFv 衔接蛋白使 CD19 特异性 CAR-T 细胞根除 ErbB2(+) 实体瘤 A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer. PubMed 2023/01/07 发表CellsQ2 · IF 6(JCR 2025) 靶点:CD19靶点:HER2技术:CAR-T实体瘤淋巴瘤白血病
TRX1 表达优化人 CAR-T 细胞的抗肿瘤功能并赋予其对促氧化肿瘤微环境的抵抗力 Expression of TRX1 optimizes the antitumor functions of human CAR T cells and confers resistance to a pro-oxidative tumor microenvironment. PubMed 2022/12/14 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:HER2技术:CAR-TB细胞淋巴瘤实体瘤淋巴瘤地区:欧洲
与肿瘤免疫治疗和生物制剂相关的心脏毒性 Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. PubMed 2021/09/25 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:HER2技术:CAR-T技术:TIL非小细胞肺癌套细胞淋巴瘤头颈部肿瘤